USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Genetics Institute Inc.
Address:
87 Cambridge Park Drive
Cambridge, MA 02140
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $240,000.00 5
SBIR Phase II $1,169,000.00 3

Award List:

STABILIZATION OF ENZYMES BY ATTACHMENT TO SOLUBLE POLYMERS

Award Year / Program / Phase:
1984 / SBIR / Phase I
Award Amount:
$40,000.00
Agency:
NSF
Principal Investigator:
J. David Rozzell Jr. , Senior Scientist
Abstract:
N/a

CURRENT TECHNIQUES FOR THE DIAGNOSIS OF GENETIC DISEASE ARE LIMITED BY AN INABILITY TO DETECT THE MAJORITY OF MUTATIONS AND POLYMORPHISMS IN DNA.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Mary collins , PRINCIPAL INVESTIGATOR
Abstract:
Current techniques for the diagnosis of genetic disease are limited by an inability to detect the majority of mutations and polymorphisms in dna. dna molecules that differ by one or a few base pairs can most efficiently be distinguished bydenaturing gradient gel electrophoresis due to sequence… More

THE OBJECTIVE OF THE PROJECT IS TO ESTABLISH HUMAN HEMATO- POIETIC PROGENITOR GROWTH FACTOR-DEPENDENT CELL LINES IN CULTURE.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Robert kamen , PRINCIPAL INVESTIGATOR
Abstract:
The objective of the project is to establish human hemato- poietic progenitor growth factor-dependent cell lines in culture. to accomplish this, researchers will first design and construct retroviral vectors that can infect and expresscloned genes in appropriate cell types. these would carry both a… More

PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES IN TRANSGENIC MICE

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Randal Kaufman , Principal Investigator
Abstract:
N/a

GENETIC ENGINEERING OF AN IMPROVED FACTOR VIII PRODUCT

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Charles Shoemaker , Principal Investigator
Abstract:
N/a

STABILIZATION OF ENZYMES BY ATTACHMENT TO SOLUBLE POLYMERS

Award Year / Program / Phase:
1987 / SBIR / Phase II
Award Amount:
$200,000.00
Agency:
NSF
Principal Investigator:
J. David Rozzell Jr. , Senior Scientist
Abstract:
Hypotheses about the stabilization of enzymes by covalent attachment to soluble polymers are to be tested in detail to isolate the effect of multi-point attachment from other factors known to affect enzyme stability including chemical modification, reduced proteolysis, diffusional effects, and… More

GENETIC ENGINEERING OF AN IMPROVED FACTOR VIII PRODUCT

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Charles Shoemaker , Principal Investigator
Abstract:
Factor viii is the plasma protein that is functionally deficient in hemophilia a patients, resulting in the clinical bleeding disorder. patients with this disease require frequent infusions of factor viii in order to main- tain hemostasis, particularly during surgery or following physical trauma.… More

PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES IN TRANSGENIC MICE

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$469,000.00
Agency:
HHS
Principal Investigator:
Randal Kaufman , Principal Investigator
Abstract:
Monoclonal antibodies have immense potential for use as prophylactic, diagnostic, and therapeutic agents in the treatment of various types of human ailments. for many usesit is desirable to use human monoclonal antibodies as opposed to murine monoclonal antibodies. although many approaches have been… More